Its story is driven by the commercial launch of Anktiva, a drug that boosts the natural immune system to treat cancer, and successful expansions into international markets like Saudi Arabia and Europe.
With recent revenue surges exceeding 100% for these specific treatments, Eli Lilly is seen as a dominant long-term growth play in healthcare. : The "Spin-Off Success". top 5 shares to buy
Broadcom has successfully positioned itself as the go-to for custom AI chips. Its story is driven by the commercial launch
AI responses may include mistakes. For financial advice, consult a professional. Learn more top 5 shares to buy
Fueling its story is an aging population and a massive boom in GLP-1 drugs like Mounjaro and Zepbound.